mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis

Area of Science:

• Hepatology
• Molecular Biology
• Pharmacology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a significant health issue, often progressing to liver cirrhosis and hepatocellular cancer.
• Current treatment options for NAFLD and its advanced stages, like non-alcoholic steatohepatitis (NASH), are limited.
• Understanding the molecular mechanisms of NASH pathogenesis is crucial for developing effective therapies.

Purpose of the Study:

• To review the pathogenesis and inflammation mechanisms in NASH.
• To identify and explore potential therapeutic targets in NASH progression.
• To highlight the mammalian target of rapamycin (mTOR) pathway as a key target for NASH treatment.

Main Methods:

• Literature review focusing on NASH pathogenesis and molecular pathways.
• Detailed examination of the role of mTOR signaling in lipogenesis, inflammation, and fibrosis.
• Analysis of mTORC1 and mTORC2 signaling pathways and their inhibition by rapamycin and analogues.
• Exploration of mTOR's regulation of adipocyte and lipogenic marker genes.

Main Results:

• The review elucidates the intricate role of mTOR in NASH pathogenesis, including its involvement in lipogenesis, inflammation, and fibrosis.
• Specific signaling pathways (mTORC1 and mTORC2) are detailed, along with their inhibition by existing mTOR inhibitors.
• mTOR's critical function in regulating key genes like PPARγ and SREBP1c is emphasized.

Conclusions:

• The mammalian target of rapamycin (mTOR) pathway presents a promising therapeutic target for NASH.
• mTOR inhibitors demonstrate potential in alleviating NASH-related inflammation and fibrosis.
• Further research into mTOR inhibitors could lead to novel treatments for NASH.